IMMUNOLOGY2026™ Conference Recordings For Attendees-A Novel Hybrid Biological-Biomaterial Vector for Antigen Delivery and Human Dendritic Cell Maturation

A Novel Hybrid Biological-Biomaterial Vector for Antigen Delivery and Human Dendritic Cell Maturation

Video Transcription

Video Summary

The talk described a new dendritic cell gene-delivery platform called the “hybrid vector,” which combines a cationic PBAE polymer shell with a bacterial carrier. The system is designed to improve DNA delivery, boost dendritic cell uptake and maturation, and ultimately enhance tumor immunotherapy. The team screened many polymer combinations and identified strong performers such as D9, which outperformed a commercial transfection reagent. They also showed that mannose modification improved dendritic cell targeting and that bacterial cargo proteins helped with unpackaging and endosomal escape. In mouse studies, the platform generated OVA-specific antibody responses. In fresh human monocyte-derived dendritic cells, the hybrid vector promoted uptake, maturation, antigen expression, T-cell proliferation, and antigen-specific T-cell expansion. The speaker concluded that this flexible system could be useful both for studying dendritic cell biology and for future ex vivo cancer immunotherapy applications.

Meta Tag

Date April 17, 2026 2:00 PM - 2:15 PM

Room 104AB

Session Targeting Adaptive Immune Responses against Cancer and Other Pathologies

Speaker Gavin Twoey

Track Vaccines and Immunotherapy (VAC)

Year 2026

Keywords

dendritic cell gene delivery

hybrid vector

PBAE polymer

tumor immunotherapy

endosomal escape

April 17, 2026 2:00 PM - 2:15 PM

104AB

Targeting Adaptive Immune Responses against Cancer and Other Pathologies

Gavin Twoey

Vaccines and Immunotherapy (VAC)

2026